Debiopharm International SA
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Subsidiary
- Established
- 1979-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://debiopharm.com
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 63
- Registration Number
- NCT03834220
- Locations
- 🇺🇦
CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipro, Ukraine
🇺🇸The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus, Ohio, United States
🇧🇷ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira, Avenida Doutor Arnaldo, São Paulo, Brazil
Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 111
- Registration Number
- NCT03723551
- Locations
- 🇺🇦
Kyiv City Clinical Hospital #8 under the Executive Body of Kyiv City Council (Kyiv City State Administration), Kyiv, Ukraine
🇺🇸Midland Florida Clinical Research Center, DeLand, Florida, United States
🇺🇸Augusta University, Augusta, Georgia, United States
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 54
- Registration Number
- NCT03270176
- Locations
- 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇷🇴Institutul Oncologic "Prof. Dr. Ion Chiricuţă" Cluj Napoca, Cluj-Napoca, Romania
🇷🇴Centrul de Oncologie, S.C. Centrul de Oncologie Sf. Nectarie S.R.L, Oncologie Medicala, Craiova, Romania
A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 20
- Registration Number
- NCT03209648
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom
Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 723
- Registration Number
- NCT02753699
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 17
- Registration Number
- NCT02726438
- Locations
- 🇺🇸
eStudySite, La Mesa, California, United States
🇺🇸Mercury St Medical Group, PLLC, Butte, Montana, United States
Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 18
- Registration Number
- NCT02595203
- Locations
- 🇬🇧
Covance Clinical Research Unit (CRU) Ltd., Leeds, United Kingdom
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
- Conditions
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 100
- Registration Number
- NCT02564744
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
Study of Debio 1450 for Bacterial Skin Infections
- Conditions
- Interventions
- First Posted Date
- 2015-04-27
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 330
- Registration Number
- NCT02426918
- Locations
- 🇺🇸
Beaumont Infectious Disease Services, Royal Oak, Michigan, United States
🇺🇸Dream Team Clinical Research, LLC, Anaheim, California, United States
🇺🇸eStudySite - Chula Vista, Chula Vista, California, United States
A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers
- First Posted Date
- 2014-08-12
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 70
- Registration Number
- NCT02214433
- Locations
- 🇺🇸
Early Phase Clinical Unit, Baltimore, Maryland, United States